Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium Therapy in Parkinson's Disease
NCT04273932Phase 1Completed
- Sponsor
- University at Buffalo
- Start
- Oct 2019
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lithium in Parkinson's disease (PD) (4 arms), sponsored by University at Buffalo. Primary endpoints: Plasma alpha-synuclein at 24 weeks, Peripheral blood mononuclear cell Nurr1 mRNA levels at 24 weeks and 3 more. Started Oct 2019; status: completed.
02
Drugs
lithium
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04273932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273932.